Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 18/20 | 0.66 |
| ▸ | CXCR1 | P25024 | 6/20 | 0.66 |
| ▸ | CCR6 | P51684 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20721262 | 0.89 | GAA (0.58) | CXCR2CXCR1CCR6GAA | |
| SCHEMBL12261147 | 0.89 | CXCR2 (0.63) | CXCR2CXCR1CCR6GAA | |
| SCHEMBL9979964 | 0.86 | GAA (0.64) | CXCR2CXCR1GAA | |
| SCHEMBL12261140 | 0.86 | CXCR2 (0.67) | CXCR2CXCR1CCR6 | |
| SCHEMBL12573300 | 0.86 | GAA (0.64) | CXCR2CXCR1CCR6GAA | |
| SCHEMBL12310775 | 0.85 | CXCR2 (0.64) | CXCR2CXCR1CCR6GAA | |
| SCHEMBL14896251 | 0.84 | GAA (0.61) | CXCR2CXCR1GAA | |
| SCHEMBL12570171 | 0.84 | CXCR2 (0.62) | CXCR2CXCR1CCR6GAA | |
| SCHEMBL12261158 | 0.83 | CXCR2 (0.62) | CXCR2CXCR1GAA | |
| SCHEMBL12261155 | 0.83 | CXCR2 (0.61) | CXCR2CXCR1CCR6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | ALLERGAN, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3668832-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | Allergan, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036374-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | ALLERGAN, INC. | 2019-02-14 | — | — | US | disclosed |
| US-20090048458-A1 | SYNTHESIS OF 2-HYDROXY-N,N-DIMETHYL-3-[[2-[[1(R)-(5-METHYL-2-FURANYL)PROPYL]AMINO]-3,4-DIOXO-1-CYCLOBUTEN-1-YL]AMINO]BENZAMIDE | SCHERING CORPORATION | 2009-02-19 | — | — | US | disclosed |
| WO-2009005801-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005802-A1 | PROCESS FOR CONTROLLED CRYSTAL SIZE IN 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS | SCHERING CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008148790-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-7462740-B2 | Synthesis of 2-hydroxy-n,n-dimethyl-3-[[2-[[1(r)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide | SCHERING CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462740-B2 | Synthesis of 2-hydroxy-n,n-dimethyl-3-[[2-[[1(r)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide | SCHERING CORPORATION (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | PHARMACOPEIA, INC. FORMERLY KNOWN AS PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | PHARMACOPEIA, INC. FORMERLY KNOWN AS PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045489-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR5, CXCR3, CCR2 | CXCR2 14/4885CXCR1 9/4885CCR6 20/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR6 19/4885 |
| US-20240400501-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CXCR2 303/4885CXCR1 156/4885CCR6 197/4885 |
| US-11208377-B2 | 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof | IL17A, TSLP, SSB | CXCR2 303/4885CXCR1 156/4885CCR6 197/4885 |
| US-20220402866-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CXCR2 303/4885CXCR1 156/4885CCR6 197/4885 |
| US-20190047947-A1 | 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF | IL17A, TSLP, SSB | CXCR2 303/4885CXCR1 156/4885CCR6 197/4885 |
| US-20090048458-A1 | SYNTHESIS OF 2-HYDROXY-N,N-DIMETHYL-3-[[2-[[1(R)-(5-METHYL-2-FURANYL)PROPYL]AMINO]-3,4-DIOXO-1-CYCLOBUTEN-1-YL]AMINO]BENZAMIDE | HTR2B, H1-0, CYP8B1 | CXCR2 1749/4885CXCR1 1823/4885CCR6 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.